Interaction study between nifedipine and recombinant tissue‐type plasminogen activator in healthy subjects

1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue‐ type plasminogen activator (rt‐PA). 2. The purpose of this randomized, double‐blind, placebo‐controlled, three‐way, cross‐over investigation was to determine t...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of clinical pharmacology Vol. 36; no. 2; pp. 99 - 104
Main Authors Boer, A, Kluft, C, Kasper, FJ, Kroon, JM, Schoemaker, HC, Breimer, DD, Soons, PA, Cohen, AF
Format Journal Article Conference Proceeding
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.08.1993
Blackwell Science
Subjects
Online AccessGet full text
ISSN0306-5251
1365-2125
DOI10.1111/j.1365-2125.1993.tb04203.x

Cover

Abstract 1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue‐ type plasminogen activator (rt‐PA). 2. The purpose of this randomized, double‐blind, placebo‐controlled, three‐way, cross‐over investigation was to determine the effect of nifedipine (20 mg orally), a compound that increases liver blood flow, on plasma concentrations of steady state endogenous and recombinant tissue‐type plasminogen activator (t‐ PA and rt‐PA) (35 mg of rt‐PA over 2 h) in nine healthy male volunteers. 3. Nifedipine increased liver blood flow by 95% (42‐167%) (mean (95% confidence interval)) as assessed by indocyanine green (ICG, 0.5 mg kg‐1 i.v. bolus injection) clearance. 4. Nifedipine did not influence the plasma concentrations of total rt‐PA antigen and activity as evaluated by the areas under the rt‐PA curves from 30 min (time at which nifedipine was ingested) to 90 min during the rt‐PA infusion (P > 0.05) and by analysis of a possible treatment x time interaction (P > 0.05). In addition, the plasma concentrations of endogenous t‐PA remained unchanged when nifedipine was given alone. 5. In conclusion, by using nifedipine as a model compound it was demonstrated that the combination of rt‐PA and a compound which increases liver blood flow probably does not lead to substantial changes in plasma concentrations of rt‐PA.
AbstractList 1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue‐ type plasminogen activator (rt‐PA). 2. The purpose of this randomized, double‐blind, placebo‐controlled, three‐way, cross‐over investigation was to determine the effect of nifedipine (20 mg orally), a compound that increases liver blood flow, on plasma concentrations of steady state endogenous and recombinant tissue‐type plasminogen activator (t‐ PA and rt‐PA) (35 mg of rt‐PA over 2 h) in nine healthy male volunteers. 3. Nifedipine increased liver blood flow by 95% (42‐167%) (mean (95% confidence interval)) as assessed by indocyanine green (ICG, 0.5 mg kg‐1 i.v. bolus injection) clearance. 4. Nifedipine did not influence the plasma concentrations of total rt‐PA antigen and activity as evaluated by the areas under the rt‐PA curves from 30 min (time at which nifedipine was ingested) to 90 min during the rt‐PA infusion (P > 0.05) and by analysis of a possible treatment x time interaction (P > 0.05). In addition, the plasma concentrations of endogenous t‐PA remained unchanged when nifedipine was given alone. 5. In conclusion, by using nifedipine as a model compound it was demonstrated that the combination of rt‐PA and a compound which increases liver blood flow probably does not lead to substantial changes in plasma concentrations of rt‐PA.
1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue-type plasminogen activator (rt-PA). 2. The purpose of this randomized, double-blind, placebo-controlled, three-way, cross-over investigation was to determine the effect of nifedipine (20 mg orally), a compound that increases liver blood flow, on plasma concentrations of steady state endogenous and recombinant tissue-type plasminogen activator (t-PA and rt-PA) (35 mg of rt-PA over 2 h) in nine healthy male volunteers. 3. Nifedipine increased liver blood flow by 95% (42-167%) (mean (95% confidence interval)) as assessed by indocyanine green (ICG, 0.5 mg kg-1 i.v. bolus injection) clearance. 4. Nifedipine did not influence the plasma concentrations of total rt-PA antigen and activity as evaluated by the areas under the rt-PA curves from 30 min (time at which nifedipine was ingested) to 90 min during the rt-PA infusion (P > 0.05) and by analysis of a possible treatment x time interaction (P > 0.05). In addition, the plasma concentrations of endogenous t-PA remained unchanged when nifedipine was given alone. 5. In conclusion, by using nifedipine as a model compound it was demonstrated that the combination of rt-PA and a compound which increases liver blood flow probably does not lead to substantial changes in plasma concentrations of rt-PA.1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue-type plasminogen activator (rt-PA). 2. The purpose of this randomized, double-blind, placebo-controlled, three-way, cross-over investigation was to determine the effect of nifedipine (20 mg orally), a compound that increases liver blood flow, on plasma concentrations of steady state endogenous and recombinant tissue-type plasminogen activator (t-PA and rt-PA) (35 mg of rt-PA over 2 h) in nine healthy male volunteers. 3. Nifedipine increased liver blood flow by 95% (42-167%) (mean (95% confidence interval)) as assessed by indocyanine green (ICG, 0.5 mg kg-1 i.v. bolus injection) clearance. 4. Nifedipine did not influence the plasma concentrations of total rt-PA antigen and activity as evaluated by the areas under the rt-PA curves from 30 min (time at which nifedipine was ingested) to 90 min during the rt-PA infusion (P > 0.05) and by analysis of a possible treatment x time interaction (P > 0.05). In addition, the plasma concentrations of endogenous t-PA remained unchanged when nifedipine was given alone. 5. In conclusion, by using nifedipine as a model compound it was demonstrated that the combination of rt-PA and a compound which increases liver blood flow probably does not lead to substantial changes in plasma concentrations of rt-PA.
Author Cohen, AF
Schoemaker, HC
Soons, PA
Boer, A
Breimer, DD
Kroon, JM
Kluft, C
Kasper, FJ
AuthorAffiliation Centre for Human Drug Research, Leiden, The Netherlands
AuthorAffiliation_xml – name: Centre for Human Drug Research, Leiden, The Netherlands
Author_xml – sequence: 1
  givenname: A
  surname: Boer
  fullname: Boer, A
– sequence: 2
  givenname: C
  surname: Kluft
  fullname: Kluft, C
– sequence: 3
  givenname: FJ
  surname: Kasper
  fullname: Kasper, FJ
– sequence: 4
  givenname: JM
  surname: Kroon
  fullname: Kroon, JM
– sequence: 5
  givenname: HC
  surname: Schoemaker
  fullname: Schoemaker, HC
– sequence: 6
  givenname: DD
  surname: Breimer
  fullname: Breimer, DD
– sequence: 7
  givenname: PA
  surname: Soons
  fullname: Soons, PA
– sequence: 8
  givenname: AF
  surname: Cohen
  fullname: Cohen, AF
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4895158$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/8398589$$D View this record in MEDLINE/PubMed
BookMark eNqVUstu1DAUtVBRmQ58ApKFEOomwY7jJGbBa8SjUiVYwNpynJuOR4k9xE7b7PoJfCNfgqOJRsACgTe2fM49vvf4nKET6ywg9ISSlMb1fJdSVvAkoxlPqRAsDTXJM8LS23todYRO0IowUiQ84_QBOvN-RwhltOCn6LRiouKVWKHuwgYYlA7GWezD2Ey4hnADYLE1LTRmbyxgZRs8gHZ9bayyAQfj_Qg_7r6HaQ943ynfG-uuYtGsdK2CG7CxeAuqC9sJ-7HegQ7-Ibrfqs7Do2Vfo6_v333ZfEwuP3242Ly5TDRngiUiI3WjM16xXBRZSxoRb_O2IFQ3FW9aVma0VQUrdAkALC9UBrUCwvNG6IxptkYvD7r7se6h0WDDoDq5H0yvhkk6ZeTviDVbeeWuZfQu5yWNAs8WgcF9G8EH2RuvoeuUBTd6WXJRkjw6v0bnfyXSkrO8JHGQSH38a1PHbpaviPjTBVdeq64dlNXGH2l5JTiNlqzRiwNND877AdojgxI5p0Pu5jG4nCMg53TIJR3yNha__qNYm6Dmv482mO7fJF4dJG5MB9N_PC7fbj7PJ_YTHMTaNw
CODEN BCPHBM
CitedBy_id crossref_primary_10_2165_00002018_200023050_00004
crossref_primary_10_1016_j_rpth_2024_102518
crossref_primary_10_1002_phar_2025
Cites_doi 10.1161/01.CIR.43.2.205
10.2165/00003495-198530030-00002
10.1111/j.1365-2125.1984.tb05003.x
10.1182/blood.V66.4.835.835
10.2165/00003088-197904060-00003
10.1002/jps.2600710205
10.1038/clpt.1986.169
10.1056/NEJM197805252982102
10.1055/s-0038-1648385
10.1055/s-0038-1657277
10.1161/01.CIR.73.2.347
10.1056/NEJM198504043121437
ContentType Journal Article
Conference Proceeding
Copyright 1993 The British Pharmacological Society
1993 INIST-CNRS
Copyright_xml – notice: 1993 The British Pharmacological Society
– notice: 1993 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
8FD
FR3
P64
RC3
7X8
5PM
DOI 10.1111/j.1365-2125.1993.tb04203.x
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Engineering Research Database
Technology Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList CrossRef
Genetics Abstracts

MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1365-2125
EndPage 104
ExternalDocumentID PMC1364571
8398589
4895158
10_1111_j_1365_2125_1993_tb04203_x
BCP4203
Genre article
Clinical Trial
Randomized Controlled Trial
Journal Article
GrantInformation_xml – fundername: British Pharmacological Society. Clinical Pharmacology Section
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOIJS
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FIJ
FUBAC
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HYE
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RPM
RX1
SUPJJ
TEORI
TR2
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
8FD
FR3
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c5393-920bdc25834962f0d93934f601cd85df3721fa636c7eee346a2ebae054d9c23c3
ISSN 0306-5251
IngestDate Thu Aug 21 18:31:49 EDT 2025
Fri Sep 05 06:59:38 EDT 2025
Thu Sep 04 17:39:11 EDT 2025
Wed Feb 19 02:35:18 EST 2025
Mon Jul 21 09:11:42 EDT 2025
Thu Apr 24 23:11:03 EDT 2025
Tue Jul 01 02:29:42 EDT 2025
Wed Jan 22 17:04:41 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Human
Intravenous administration
Pyridine(dihydro) derivative
Oral administration
Drug interaction
Normal
Pharmacokinetics
Blood plasma
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
CC BY 4.0
LinkModel OpenURL
MeetingName British Pharmacological Society. Clinical Pharmacology Section. Meeting
MergedId FETCHMERGED-LOGICAL-c5393-920bdc25834962f0d93934f601cd85df3721fa636c7eee346a2ebae054d9c23c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ObjectType-Undefined-3
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.1993.tb04203.x
PMID 8398589
PQID 1753470349
PQPubID 23462
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_1364571
proquest_miscellaneous_75970499
proquest_miscellaneous_1753470349
pubmed_primary_8398589
pascalfrancis_primary_4895158
crossref_primary_10_1111_j_1365_2125_1993_tb04203_x
crossref_citationtrail_10_1111_j_1365_2125_1993_tb04203_x
wiley_primary_10_1111_j_1365_2125_1993_tb04203_x_BCP4203
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate August 1993
PublicationDateYYYYMMDD 1993-08-01
PublicationDate_xml – month: 08
  year: 1993
  text: August 1993
PublicationDecade 1990
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: London
– name: England
PublicationTitle British journal of clinical pharmacology
PublicationTitleAlternate Br J Clin Pharmacol
PublicationYear 1993
Publisher Blackwell Publishing Ltd
Blackwell Science
Publisher_xml – name: Blackwell Publishing Ltd
– name: Blackwell Science
References 1971; 43
1982; 48
1971; 71
1979; 298
1986; 40
1986; 73
1984; 17
1979; 4
1985; 312
1985; 30
1961; 21
1985; 66
1992; 67
Verheijen JH (e_1_2_1_11_2) 1982; 48
Caesar J (e_1_2_1_10_2) 1961; 21
e_1_2_1_6_2
e_1_2_1_7_2
e_1_2_1_4_2
e_1_2_1_5_2
e_1_2_1_3_2
e_1_2_1_12_2
Boer A (e_1_2_1_2_2) 1992; 67
e_1_2_1_13_2
e_1_2_1_14_2
e_1_2_1_8_2
e_1_2_1_9_2
References_xml – volume: 71
  start-page: 157
  year: 1971
  end-page: 160
  article-title: High pressure liquid chromatographic analysis of indocyanine green
  publication-title: J pharm Sci
– volume: 21
  start-page: 43
  year: 1961
  end-page: 57
  article-title: The use of indocyanin green in the measurement of hepatic blood flow and as a test of hepatic function
  publication-title: Clin Sci
– volume: 298
  start-page: 1160
  year: 1979
  end-page: 1163
  article-title: Lidocaine kinetics predicted by indocyanine green clearance
  publication-title: New Engl J Med
– volume: 40
  start-page: 239
  year: 1986
  end-page: 242
  article-title: Changes in antipyrin and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy
  publication-title: Clin Pharmac Ther
– volume: 43
  start-page: 205
  year: 1971
  end-page: 211
  article-title: Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man
  publication-title: Circulation
– volume: 17
  start-page: 83
  year: 1984
  end-page: 85
  article-title: Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects
  publication-title: Br J clin Pharmac
– volume: 73
  start-page: 347
  year: 1986
  end-page: 352
  article-title: Acute coronary reocclusion after thrombolysis with recombinant human tissue‐type plasminogen activator: prevention by a maintenance infusion
  publication-title: Circulation
– volume: 312
  start-page: 932
  year: 1985
  end-page: 936
  article-title: The thrombolysis in myocardial infarction (TIMI) trial
  publication-title: New Engl J Med
– volume: 67
  start-page: 83
  year: 1992
  end-page: 87
  article-title: Liver blood flow as a major determinant of the clearance of recombinant human tissue‐type plasminogen activator
  publication-title: Thromb Haemostas
– volume: 48
  start-page: 266
  year: 1982
  end-page: 269
  article-title: A simple, sensitive spectrophotometric assay for extrinsic (tissue‐type) plasminogen activator applicable to measurement in plasma
  publication-title: Thromb Haemostas
– volume: 66
  start-page: 835
  year: 1985
  end-page: 839
  article-title: Tissue plasminogen activator release in vivo in response to vasoactive agents
  publication-title: Blood
– volume: 30
  start-page: 182
  year: 1985
  end-page: 274
  article-title: Nifedipine—A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischemic heart disease, hypertension and related cardiovascular disorders
  publication-title: Drugs
– volume: 4
  start-page: 433
  year: 1979
  end-page: 448
  article-title: Drug kinetics and hepatic blood flow
  publication-title: Clin Pharmacokin
– ident: e_1_2_1_3_2
  doi: 10.1161/01.CIR.43.2.205
– ident: e_1_2_1_7_2
  doi: 10.2165/00003495-198530030-00002
– ident: e_1_2_1_9_2
  doi: 10.1111/j.1365-2125.1984.tb05003.x
– ident: e_1_2_1_6_2
  doi: 10.1182/blood.V66.4.835.835
– ident: e_1_2_1_5_2
  doi: 10.2165/00003088-197904060-00003
– ident: e_1_2_1_12_2
  doi: 10.1002/jps.2600710205
– ident: e_1_2_1_8_2
  doi: 10.1038/clpt.1986.169
– ident: e_1_2_1_4_2
  doi: 10.1056/NEJM197805252982102
– volume: 21
  start-page: 43
  year: 1961
  ident: e_1_2_1_10_2
  article-title: The use of indocyanin green in the measurement of hepatic blood flow and as a test of hepatic function
  publication-title: Clin Sci
– volume: 67
  start-page: 83
  year: 1992
  ident: e_1_2_1_2_2
  article-title: Liver blood flow as a major determinant of the clearance of recombinant human tissue‐type plasminogen activator
  publication-title: Thromb Haemostas
  doi: 10.1055/s-0038-1648385
– volume: 48
  start-page: 266
  year: 1982
  ident: e_1_2_1_11_2
  article-title: A simple, sensitive spectrophotometric assay for extrinsic (tissue‐type) plasminogen activator applicable to measurement in plasma
  publication-title: Thromb Haemostas
  doi: 10.1055/s-0038-1657277
– ident: e_1_2_1_14_2
  doi: 10.1161/01.CIR.73.2.347
– ident: e_1_2_1_13_2
  doi: 10.1056/NEJM198504043121437
SSID ssj0013165
Score 1.4487329
Snippet 1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue‐ type plasminogen...
1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue-type plasminogen...
1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue- type plasminogen...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 99
SubjectTerms Adult
Biological and medical sciences
Blood Pressure - drug effects
Blood. Blood coagulation. Reticuloendothelial system
Double-Blind Method
Drug Interactions
Heart Rate - drug effects
Humans
Indocyanine Green - metabolism
Kinetics
Liver Circulation - drug effects
Male
Medical sciences
Nifedipine - pharmacology
Pharmacology. Drug treatments
Recombinant Proteins - blood
Tissue Plasminogen Activator - blood
Title Interaction study between nifedipine and recombinant tissue‐type plasminogen activator in healthy subjects
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2125.1993.tb04203.x
https://www.ncbi.nlm.nih.gov/pubmed/8398589
https://www.proquest.com/docview/1753470349
https://www.proquest.com/docview/75970499
https://pubmed.ncbi.nlm.nih.gov/PMC1364571
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9NAEF2FckHiwEcrDBQWCfWSOrK9a3tzpKVRaYBEkEi9WfbaFkHUiUiCCL-FH8vMerPetImgXCzLX4n1nmd3ZmfeEPK6THmcSha6gHDpchlJ-KQ4c4UsozLPhV-mGBr48DE6H_OLy_Cy1fptZS0tF1lH_tpaV_I_qMIxwBWrZG-BrHkoHIB9wBe2gDBsb2K8dahZaxJZAhCm1nHWqFKvbGaoIKBuEa7UZU2yFua55NjMul5TQGf5KlOpMu2FAshVEdsZzLivJtUU_pfS4viBjjsGTuqiylV7vswwvNP0rD9rnwzqlIvGwr8f90YbYdr-m8_D-qJep1mt6n8aDFQqwkVHR25zXbTHTIbc9VikNliWkQOXBZxhLTqrLXItiaKZF1jmte6lpAdq3bd49xigEvhgAocVmQxD4Dzw2Do71BbevjYgmjRFLmD-GYo75G7AYoGNQd6-6zdrVL5qVGreQEva6jyxHT--Mf25P0vnwIeybqGyzce5mapru1BqDjR6QPab6lA6NGR8SFpF9YgcDWu2rY7pqCnpmx_TIzq0ePiYfLXoRxX9qKYfbehHgX7Uoh-16Ect-lFDPzqpqKYfXdNvn4x7Z6PTc1c3_HBlyIA13cDLchmEArsYBKWXd-EoLyPPl7kI85LFAdiOiEUyLoqC8SgNiiwtwOvIuzJgkh2QvWpaFU8I5WkcFYXvxVkq4AmAXhpFXGBlNQs8kTuku8YhkVoNH5uyfEssrxgwTBDDBDFMNIbJT4cwc--s1oT5p7sON-A2t2qWOeTVGv4ETDyu26VVMV3OExTT5TEKSTnk5Y5r4rAbY_TCIQc1YczjwQMSoYAT8QaTzHnUl988U02-KJ15H1MUYt8hQnHuFu-anJwOce_pX975GbnXmIvnZG_xfVkcwiR_kb1Q39ofw8P9Bg
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=proceeding&rft.title=British+journal+of+clinical+pharmacology&rft.atitle=Interaction+study+between+nifedipine+and+recombinant+tissue-type+plasminogen+activator+in+healthy+subjects&rft.au=DE+BOER%2C+A&rft.au=KLUFT%2C+C&rft.au=KASPER%2C+F.+J&rft.au=KROON%2C+J.+M&rft.date=1993-08-01&rft.pub=Blackwell+Science&rft.issn=0306-5251&rft.volume=36&rft.issue=2&rft.spage=99&rft.epage=104&rft_id=info:doi/10.1111%2Fj.1365-2125.1993.tb04203.x&rft.externalDBID=n%2Fa&rft.externalDocID=4895158
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon